Please assess the completion status of the following clinical trial:

Trial Title: Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patients, within age limits as defined by local regulations and local product label, who have previously been treated with, who are currently being treated with or initiating treatment with ranibizumab for any approved indication included in the local product label~* Willing and able to provide informed written consent personally or by legal proxy~Exclusion Criteria:~* Simultaneous participation in a study that includes administration of any investigational drug or procedure~* Systemic or ocular treatment with any VEGF inhibitor other than ranibizumab in the 90 days prior to enrollment~* Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ranibizumab (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).